[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Novikov et al., 2020 - Google Patents

Molecular basis of COVID-19 pathogenesis

Novikov et al., 2020

View PDF
Document ID
12627012658251653903
Author
Novikov F
Stroylov V
Svitanko I
Nebolsin V
Publication year
Publication venue
Russian Chemical Reviews

External Links

Snippet

The review summarizes the publications, available at the time it was written, addressing the chemical and biological processes that occur in the human body upon exposure to coronaviruses, in particular SARS-CoV-2. The mechanisms of viral particle entry into the …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application

Similar Documents

Publication Publication Date Title
Astuti Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response
Zhou et al. Potential therapeutic targets and promising drugs for combating SARS‐CoV‐2
Shah et al. Overview of immune response during SARS-CoV-2 infection: lessons from the past
Novikov et al. Molecular basis of COVID-19 pathogenesis
Kumar et al. Role of host-mediated post-translational modifications (PTMs) in RNA virus pathogenesis
Asghari et al. The novel insight of SARS-CoV-2 molecular biology and pathogenesis and therapeutic options
García-Pérez et al. Taming the Autophagy as a Strategy for Treating COVID-19
Gelman et al. Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents
Alipoor et al. COVID-19: molecular and cellular response
Sohag et al. Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review
Zhang et al. Overview of targets and potential drugs of SARS-CoV-2 according to the viral replication
Dube et al. Repurposed drugs, molecular vaccines, immune‐modulators, and nanotherapeutics to treat and prevent COVID‐19 associated with SARS‐CoV‐2, a deadly nanovector
Xia et al. Emerging roles of extracellular vesicles in COVID‐19, a double‐edged sword?
Zhand et al. COVID-19: The immune responses and clinical therapy candidates
Richman et al. Antiviral therapy
Kohli et al. Endoplasmic reticulum chaperones in viral infection: therapeutic perspectives
Stevaert et al. Betulonic acid derivatives interfering with human coronavirus 229E replication via the nsp15 endoribonuclease
Singh et al. SARS-CoV-2 therapeutics: how far do we stand from a remedy?
Kotta et al. Combating the pandemic COVID-19: clinical trials, therapies and perspectives
Kumar et al. The chronicle of COVID-19 and possible strategies to curb the pandemic
Qu et al. The potential effects of clinical antidiabetic agents on SARS‐CoV‐2
Essa et al. Antiviral peptides against SARS-CoV-2: therapeutic targets, mechanistic antiviral activity, and efficient delivery
Rauf et al. Nano‐therapeutic strategies to target coronavirus
Oliver et al. Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus
Shin et al. Towards goals to refine prophylactic and therapeutic strategies against COVID-19 linked to aging and metabolic syndrome